AMPATH-Oncology Institute: HPV and Cervical Cancer in Kenyan Women with HIV/AIDS

AMPATH-肿瘤学研究所：感染艾滋病毒/艾滋病的肯尼亚妇女中的 HPV 和宫颈癌

基本信息

批准号：
8794571
负责人：
DARRON R BROWN
金额：
$ 72.82万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-09-19 至 2019-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8794571
关键词：
Acetic Acids Acquired Immunodeficiency Syndrome Address Africa Africa South of the Sahara American Anti-Retroviral Agents Behavioral Biological Factors Biometry Cancer Etiology Cervical Cervical Intraepithelial Neoplasia Cervical dysplasia Cervix Neoplasms Cessation of life Clinical Cold Therapy Comorbidity Correlative Study Country Databases Development Diagnosis Disease Emerging Technologies Environment Family Fostering Foundations Future HIV HPV-High Risk Human Papillomavirus Human papilloma virus infection Human papillomavirus 16 Incidence Income Infection Institutes Kenya Laboratories Lesion Life Local Therapy Loop electrosurgical excision procedure Malignant Neoplasms Malignant neoplasm of cervix uteri Medical Research Mentors Natural History Nurses Oncogenic Outcome Outcomes Research Patients Physicians Pilot Projects Population Premalignant Prevention Public Health Reporting Research Research Institute Research Personnel Research Training Risk Factors Scientist Sex Behavior Sexually Transmitted Diseases Solid Tissue Banking Tissue Banks Training United States Universities Vaccines Virus Visual Woman Work anticancer research base biobank cancer diagnosis carcinogenesis data management high risk sexual behavior mortality multidisciplinary nutrition oncology programs public health relevance screening

项目摘要

The interaction of human papillomavirus (HPV) with human immunodeficiency virus (HIV) represents one of the most "dangerous liaisons" for women in Sub-Saharan Africa. In high-income countries, the most common of these high-risk HPVs (HR-HPVs) are HPV 16 and 18, which are the targets of two commercially available bivalent and quadrivalent vaccines. However, a wider spectrum of HR-HPV types and a higher incidence of multiple HPV infections have been reported in women from low- to middle-income countries (LMCs). Worldwide, it is estimated that over 500,000 cases of cervical cancer are diagnosed yearly, with 85% of these in LMCs. In Africa, approximately 80,000 women are diagnosed with cervical cancer and 60,000 die from the disease annually, making it the leading cause of cancer death among women. Sub-Saharan Africa also contains 70% of the world's diagnosed cases of HIV, with Kenya as one of Africa's epicenters. Recent studies show that HIV is clearly a contributing factor for cervical carcinogenesis; HIVinfected women have a greater incidence and persistence of HPV infections and suffer from a markedly higher incidence of cervical cancer and cervical intraepithelial neoplasia (CIN). The "perfect storm" of these two families of viruses only begins to explain why both incidence and mortality of cervical cancer in Sub- Saharan Africa are three-fold that of the United States. Other co-morbidity factors, such as sexually transmitted infections (STIs), environmental issues, anti-retroviral and other therapies, and their relation to HR-HPV carcinogenesis, need further study if a major impact is to be made in cervical cancer. The core objective of this application is to better understand the natural history of oncogenic HPV infections in HIV-infected Kenyan women, and the potentially modifiable (and non-modifiable) factors that are associated with progression of oncogenic HPV infection to clinical disease, including cervical cancer. Additionally, with the creation of a multinational, transdisciplinary program entitled the AMPATH-Oncology Institute, a mentoring program will be established to foster development of new cancer researchers in Kenya. Our expected outcome is the establishment of a dedicated core of cancer-focused Kenyan investigators who embody a culture of translational and collaborative research.

人类乳头瘤病毒（HPV）与人免疫缺陷病毒（HIV）的相互作用代表撒哈拉以南非洲妇女最“危险的联络人”。在高收入国家，最常见的国家这些高风险的HPV（HR-HPV）为HPV 16和18，这是两个市售的目标二价和四价疫苗。但是，较宽的HR-HPV类型和更高的发生率来自低收入国家（LMC）的女性（LMC）的女性已经报道了多种HPV感染。在全球范围内，据估计，每年被诊断出500,000例宫颈癌，其中85％这些在LMC中。在非洲，大约80,000名妇女被诊断出患有宫颈癌和60,000名死亡每年从该疾病中脱颖而出，使其成为女性癌症死亡的主要原因。撒哈拉以南非洲还包含70％的世界诊断出艾滋病毒案件，肯尼亚是非洲的之一中心。最近的研究表明，艾滋病毒显然是宫颈癌发生的因素。 Hivincted 妇女的发病率和持久性HPV感染率更大，并且患有明显的痛苦宫颈癌和宫颈上皮内肿瘤（CIN）的发病率更高。这些的“完美风暴” 两个病毒家族仅开始解释为什么子宫颈癌的发病率和死亡率均在亚宫颈癌中撒哈拉非洲是美国的三倍。其他合并症因素，例如性别传播感染（STI），环境问题，抗逆转录病毒和其他疗法及其与 HR-HPV癌变，如果要对宫颈癌产生重大影响，则需要进一步研究。该应用的核心目的是更好地了解致癌性HPV感染的自然历史在艾滋病毒感染的肯尼亚妇女中，以及潜在的可修改（和不可修改）的因素与临床疾病（包括宫颈癌）的致癌性HPV感染有关。此外，通过创建跨国，跨学科的计划，名为《及及综合学》研究所将建立一项指导计划，以促进肯尼亚的新癌症研究人员的发展。我们的预期结果是建立了一个专门的以癌症为中心的肯尼亚调查员的核心体现一种转化和协作研究的文化。